Plain-English translation of NCT07177794 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This trial is testing whether —an immunotherapy drug that helps your immune system fight cancer—combined with a low-dose chemotherapy pill called can help prevent esophageal cancer from coming back after you've finished radiation and chemotherapy treatment. The study will compare people who receive this combination therapy for up to one year with people who receive standard follow-up care alone.
Even after successful radiation and chemotherapy, esophageal cancer often returns. This trial is trying to find a way to reduce that recurrence risk by using the medication to boost your immune system's ability to keep the cancer away long-term.
You likely qualify if…
You likely don't qualify if…
If you are randomly assigned to the treatment group, you will receive an intravenous infusion of once every three weeks for up to 16 doses (about 12 months), and you will take pills by mouth twice daily throughout that period. If you are assigned to the observation group, you will receive standard follow-up care without the medication. Both groups will have regular clinic visits and tests to monitor your health and check whether the cancer has returned.
AI-generated summary from trial data · Jun 4, 2026 · Not medical advice
China